Last reviewed 2026-05-14 · How we verify

ascending dose of GSK1292263

GlaxoSmithKline · Phase 1 active Small molecule

ascending dose of GSK1292263 is a Small molecule drug developed by GlaxoSmithKline. It is currently in Phase 1 development.

At a glance

Generic name	ascending dose of GSK1292263
Sponsor	GlaxoSmithKline
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study in Healthy Volunteers of Single Doses of Orally Administered Investigational Product to Investigate Safety, Tolerability, and Pharmacokinecs. (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ascending dose of GSK1292263 CI brief — competitive landscape report
ascending dose of GSK1292263 updates RSS · CI watch RSS
GlaxoSmithKline portfolio CI

Frequently asked questions about ascending dose of GSK1292263

What is ascending dose of GSK1292263?

ascending dose of GSK1292263 is a Small molecule drug developed by GlaxoSmithKline.

Who makes ascending dose of GSK1292263?

ascending dose of GSK1292263 is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).

What development phase is ascending dose of GSK1292263 in?

ascending dose of GSK1292263 is in Phase 1.

Manufacturer: GlaxoSmithKline — full pipeline
Compare: ascending dose of GSK1292263 vs similar drugs
Pricing: ascending dose of GSK1292263 cost, discount & access